Antidepressants are commonly prescribed for depression but their efficacy is questionable - many people don't experience symptom relief.
The National Institute of Mental Health's STAR*D study, the largest and longest study ever conducted to evaluate depression treatment, may have a better way; identifying predictors of antidepressant response. f
Approximately one-third of patients responded within their initial medication trial and approximately one-third of patients did not have an adequate clinical response after being treated with several different medications. Identifying predictors of antidepressant response could help optimize treatment. A paper in Biological Psychiatry outlines progress in identifying genomic predictors of antidepressant response.
Previous studies have searched for genetic markers that may predict antidepressant response, despite not knowing the contribution of genetic factors, say Dr. Katherine Tansey of the Institute of Psychiatry at King's College London and colleagues who resolved to address the issue.
"Our study quantified, for the first time, how much is response to antidepressant medication influenced by an individual's genetic make-up," said Tansey.
The researchers estimated the magnitude of the influence of common genetic variants on antidepressant response using a sample of 2,799 antidepressant-treated subjects with major depressive disorder and genome-wide genotyping data. They found that genetic variants explain 42% of individual differences, and therefore, significantly influence antidepressant response.
"While we know that there are no genetic markers with strong effect, this means that there are many genetic markers involved. While each specific genetic marker may have a small effect, they may add up to make a meaningful prediction," Tansey added.
"We have a very long way to go to identify genetic markers that can usefully guide the treatment of depression. There are two critical challenges to this process," said Dr. John Krystal, Editor of Biological Psychiatry. "First, we need to have genomic markers that strongly predict response or non-response to available treatments. Second, markers for non-response to available treatments also need to predict response to an alternative treatment. Both of these conditions need to be present for markers of non-response to guide personalized treatments of depression."
"Although the Tansey et al. study represents progress, it is clear that we face enormous challenges with regards to both objectives," he added. "For example, it does not yet appear that having a less favorable genomic profile is a sufficiently strong negative predictor of response to justify withholding antidepressant treatment. Similarly, there is lack of clarity as to how to optimally treat patients who might have less favorable genomic profile."
Additional research is certainly required, but scientists hope that one day, results such as these can lead to personalized treatment for depression.